Safety Issues Clinical Trial
Official title:
Parallel Group Randomized Controlled Trial to Assess the Impact of Medication Reconciliation at Hospital Admission on Healthcare Outcomes
Medication reconciliation is a systematic process by which health care professionals obtain
the most complete and accurate information about the drugs regularly taken by patients.
Internationally, the value of this procedure is mainly attributed to the reduction in the
number of adverse drug events, which can cause drug-related morbidity and mortality, as well
as unnecessary health care costs.
As part of the Progress! Pilot project Safe Pharmacotherapy at the interface points, promoted
by the Federal Office of Public Health, coordinated by the Swiss Patients Safety Foundation
and held in several Swiss hospitals, medication reconciliation at hospital admission was
introduced at the regional hospital Beata Vergine in Mendrisio, from 2014 to 2016. During
this pilot project it was shown that medication reconciliation after obtaining the best
possible medication history by a pharmacist at hospital admission, in comparison with the
standard medication history obtained by the physician at admission, reduced the number of
clinically relevant drug discrepancies.
A structured, well-established and practicable procedure of medication reconciliation that
improves patient safety assuring a better quality of care at hospital admission might provide
evidence that medication reconciliation could be a valuable intervention to be applied
systematically in all EOC hospitals at admission, as well as subsequently potentially at the
other hospital interfaces.
The purpose of this study is to evaluate whether obtaining the best possible medication
history and performing medication reconciliation at hospital admission results in improving
some specific healthcare outcomes.
The study seeks primarily to determine if obtaining the best possible medication history and
performing medication reconciliation, in comparison with the standard medication history,
reduces the number of subsequent unplanned all-cause hospital visits (readmissions and
emergency department visits within 30 days after initial discharge). As secondary objectives,
the study aims at assessing if best possible medication history with medication
reconciliation, in comparison with the standard medication history, reduces the incidence of
adverse drug reactions during hospital stay, shortens length of stay, leads to a reduction in
the use of hospital resources, and/or is associated with a decreased number of deaths.
Patients of the control group will not receive the best possible medication history with
medication reconciliation at admission. The standard physician-acquired medication history
will be performed as usual.
Eligible patients, randomized within the intervention arm, will receive medication
reconciliation according to the following steps:
1. The pharmacy assistant will obtain the best possible medication history by compiling a
comprehensive list of the medications the patient is taking and details about how the
drugs are taken. In order to confirm the accuracy of the history, the pharmacy assistant
will use at least two sources of information, one of which being, when possible, the
interview with the patient and/or family members, in addition to referral letters,
prescriptions and drug lists from primary care centres, and other.
2. The clinical pharmacist will reconcile best possible medication history with prescribed
medicines and, to resolve unclear or ambiguous discrepancies between the two lists
and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will
refer to the medical doctor.
3. The medical doctor will decide potential changes in pharmacotherapy and communicate them
to the patient providing complete information on medicines.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Not yet recruiting |
NCT04774900 -
Standardization of Ambulance Equipment
|